Development and domestic manufacture of adjuvanted, pandemic influenza vaccines

Active Indefinite Delivery Contract Awarded Last action

Contract number
75A50120D00002
Awardee
Awarding agency
Task orders
0

Award facts

Opportunity
Last date to order 62% complete
IDV ceiling
$6,338,039,491.48
Maximum order
$200,000,000.00
Award type
Single award
Who can order
Only the awarding agency
Contracting staff
Set-aside
No set-aside
Competition
Not Competed · 1 offer Only One Source
Pricing
Cost Plus Fixed Fee
Legislative mandates

Award details come from SAM.gov/FPDS.

About this IDV

Written by GovTribe AI ·

This Indefinite Delivery Contract, awarded to Sanofi Vaccines US Inc. (division of Sanofi Pasteur Inc.) on December 5, 2019, establishes a single-award vehicle for the development and domestic manufacture of adjuvanted pandemic influenza vaccines. The contract, funded by the Office of the Assistant Secretary for Preparedness and Response (a civilian agency within the Department of Health and Human Services), carries a ceiling value of $6.34 billion and extends through December 31, 2030. The procurement represents a critical component of the federal government's pandemic preparedness strategy, leveraging Sanofi Pasteur's established expertise as a major domestic vaccine manufacturer. The contract structure includes incentive fee mechanisms tied to specific milestones, with modifications to the incentive fee schedule implemented as recently as April 2025, demonstrating ongoing program management and performance refinement. To date, $2.45 million in incentive fees have been earned against Contract Line Item Number 0002.

The contract scope encompasses development activities, manufacturing capabilities, and delivery of pandemic influenza vaccines formulated with adjuvants—immunological enhancers designed to boost vaccine efficacy. As a single-award indefinite delivery vehicle without set-aside utilization, the contract provides the government with flexibility to issue task orders for vaccine quantities and delivery schedules based on pandemic response needs and public health requirements. This arrangement ensures domestic surge capacity and supply chain security for a critical medical countermeasure, aligning with the federal government's strategic objective to maintain vaccine manufacturing infrastructure capable of responding to influenza pandemic threats. Sanofi Pasteur's Pennsylvania-based manufacturing facility serves as the primary place of performance, positioning the contractor as a key provider supporting national immunization programs and public health emergency preparedness objectives.

Transactions

Action Obligated Date
Other Administrative Action P00017 · The purpose of this modification is to: $0
Supplemental Agreement for work within scope P00016 · The purpose of this modification is to: 1) add funding in the amount of $44,000,000.00 to clin 0003 development - pre-clinical & clinical phases 1 and 2 to… $44,000,000
Other Administrative Action P00015 · At no cost to the government, extend the period of performance for clins 0002, 0003, 0005, 0006, and 0059 for the retrofit recombinant facility and… $0
Other Administrative Action P00014 · The purpose of this modification is to extend the period of performance of clin 004 & change clin 006 line type $0
Funding Only Action P00013 · The purpose of this modification is to revise section B.3.2 - option period 1 (clin 0004) to reflect the cost overrun in the total amount of $13,418,350. $13,418,350
Other Administrative Action P00012 · Incorporate travel language into section B.5, advanced understandings $0
Other Administrative Action P00011 · Change COR of contract from arlene joyner to aminata alharazim. $0
Other Administrative Action P00010 · Incorporate hhsar clause 352.232-71, electronic submission of payment requests into section I of the contract and to also either add or update invoice… $0
Other Administrative Action P00009 $0
Exercise an Option P00008 $90,736,358
Change Order P00007 $160,000,000
Supplemental Agreement for work within scope P00005 $0
Exercise an Option P00006 $5,079,008
Other Administrative Action P00004 $0
Other Administrative Action P00002 -$73,138,860
Funding Only Action P00003 $73,138,860
Exercise an Option P00001 $73,138,860
Original award $225,852,500
Show all 18

Quick answers

Who was awarded contract 75A50120D00002?

75A50120D00002 was awarded to Sanofi Vaccines US Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on December 5, 2019.

How much is contract 75A50120D00002 worth?

75A50120D00002's own ceiling is $6,338,039,491. A single order can be worth up to $200,000,000.

Who can order from contract 75A50120D00002?

75A50120D00002 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.

Was contract 75A50120D00002 competed?

The extent of competition for 75A50120D00002 was not competed. The government received 1 offer.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV
Try for free Login